口腔颌面外科杂志2025，Vol.35Issue(1)：53-58,6.DOI:10.12439/kqhm.1005-4979.2025.01.009
风险期及0期药物相关性颌骨坏死的研究进展
Research progress on the at-risk category and stage 0 of medication-related osteonecrosis of the jaw
摘要
Abstract
Medication-related osteonecrosis of the jaw(MRONJ)is a metabolic disorder and a form of jaw osteonecrosis that arises from the use of bisphosphonates,anti-angiogenic drugs,and other medications in the treatment of conditions such as malignant tumor bone metastasis and osteoporosis.The American Association of Oral and Maxillofacial Surgeons(AAOMS)has categorized MRONJ into five stages based on clinical manifestations.Within this classification,the at-risk category encompasses asymptomatic patients who have received intravenous or oral antiresorptive therapy but show no apparent necrotic bone.Stage 0 refers to patients who exhibit no clinical evidence of necrotic bone yet present with nonspecific symptoms or clinical and radiographic findings.Presently,the diagnosis and treatment of stage 0 MRONJ still exhibit uncertainties.There is controversy regarding the effective prevention of progression from at-risk and stage 0 patients to established MRONJ.This article reviews the diagnostic approaches and current treatment status of stage 0 MRONJ,analyzes the clinical practices and research findings concerning invasive oral procedures for at-risk patients,and highlights the controversies and uncertainties within the current research field.The aim is to provide valuable insights and references for future scientific research and clinical practice.关键词
药物相关性颌骨坏死/骨改良药物/口腔并发症/诊断/预防/治疗Key words
medication-related osteonecrosis of the jaw/bone-modifying agents/oral complications/diagnosis/prevention/treatment分类
口腔医学引用本文复制引用
杨沐,康非吾,张雪明..风险期及0期药物相关性颌骨坏死的研究进展[J].口腔颌面外科杂志,2025,35(1):53-58,6.基金项目
国家自然科学基金(82271013) （82271013）
上海市科委"科技创新行动计划"医学创新研究专项(22Y11903100) （22Y11903100）
同济大学中央高校基本科研业务费专项资金自主原创项目(22120240389) （22120240389）
